Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Eucure Approved for US Phase II Trials of Combination Therapies

publication date: Jul 7, 2021

Eucure Biopharma, a Beijing immunotherapy subsidiary of Biocytogen, has been approved to start US Phase II trials of two antibodies. The candidates are YH001, targeting CTLA-4, and YH003, targeting CD40.  Both molecules will be tested in combination with Junshi Biosciences' anti-PD-1, toripalimab. Eucure, which develops innovative immunotherapies to meet clinical needs for global markets, has built a product pipeline of more than 10 targets. The parent, Biocytogen, is a CRO that provides gene-modified animal models for drug discovery and preclinical testing. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Singapore and Digital
April 26-27, 2023
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China